4 курс / Акушерство и гинекология / Журавлева_Е_В_Патогенетическая_профилактика_повторных_преэклампсий

7. ОтменаНМГза24часадопланируемойоперацкесареч вания

возобновлениеегопримененияспустячас10 слеперациив

геморрагичосложн. ескихний

131

Практическиерекомендации

3. Длясвоевремобоснованнойпатогенетически профилактики повторныхПЭрекомендованоначатьтерапию,

включающуюантикоагулянтную,антиагтервапиюегантную сочетаниимикронизированнымпрогестероном,фолиевой кислот,антиоивитаминамийксидантагруппыВ, и

фертцилклараьисроковннихбеременностигодо(

завепршеноцессовплацентациинвазиятрофобласта), ии

течениевсг гостацпроцеивпослеронногоса довом периоде.

4.Необходимкомплексрегулярныйтроль эффективностибезопаснтерапии,включающийстиценку клиническихотсутствие(признаковгеморрагичексих осложнений,тромбозов,отсутствиепризнаковСЗВРП

132

133

Сплитературысок

134

135

[19]МакацарияА.Д.Бицадзе, ,АкиньшинаС.В.Применение низкомолекулярнгепаринавакушерск,гинекологическоййго

онкологическойпрактике// Consilium medicum. – 2005. – Т. 7. – №7. – С.556 - 565.

136

[26]Aggarwal PK, Jain V, Jha V. Endothelial nitric oxide synthase, angiotensinconverting enzyme and angiotensinogen gene polymorphisms in hypertensive disorders of pregnancy // Hypertens Res. 2010 May;33(5):473-7.

[27]Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences // Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2200-7

[28]Alfirevic Z, Roberts D et al. How strong is the association between maternal thrombophilia and adverse pregnancy outcomes. A systematic review. Eur.J. Obstet.Gyn.Reprod.Biol. 2002; 101 (1): 6-14

[29]Alijotas-Reig J, Vilardell-Tarres M. Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies? // Obstet Gynecol Surv. 2010 Jan;65(1):39-45.

[30]Amoroso E.C. Placentation. In:Parker AS, ed. Marshalls Physiology of Reproduction. 3rd ed. London: Longmans, Green and Co. 1952:127-311

[31]APASS Investigators. Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke. JAMA. 2004; 291:576-584

[32]Arnout J. Detection of antiphospholipid antibodies // Thromb. Haemost. — 2003; ISSN 1740 3340 (Suppl): (abstr SY68).

[33]Asherson R.A., Cervera R., Piette J.C., Font J., Lie J.T., Burcoglu A., Lim K., Munoz-Rodriguez F.J., Levy R.A., Boue F., Rossert J., Ingelmo M. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients // Medicine (Baltimore). 1998 May;77(3):195-207.

[34]Asherson RA. The Catastrophic Antiphospholipid Syndrome (Asherson’s Syndrome). Monograph. Johannesburg. 2005

[35]Balta G, Altay C, Gurgey A.PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs //Am J Hematol. 2002 Oct;71(2):89-93.

137

[36]Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the seventh ACCP Conference on antithrombotic and thrombolytic therapy // Chest. 2004;126:627S–643S.

[37]Bauer S, Pollheimer J, Hartmann J et al. Tumor necrosis factoraipha inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in first trimester villous explants cultures. J .Clin.Endocrinol.Metab. 2004; 89 (2): 812-822

[38]Benedetto C, Marozio L, Saslton L, Maula V, Chippa G, Massobrio I. Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome // Acta Obstet Gynecol Scand. 2002;81: 1095-1100.

[39]Bick RL, Frenkel EP, Backer WF, Sarode R. Hematological complications in obstetrics, pregnancy, and gynecology // UK, Cambridge University press, 2006. P 604

[40]Bodnar LM, Ness RB, Markovic N, Roberts JM. The risk of preeclampsia rises with increase pregnancy body mass index. Ann Epidemiol 2005; 15: 475-82

[41]Bonnar J, Redman CW, Denson KW. The rol of coagulation and fibrinolysis in preeclampsia. Perspect.Nephrol.Hypertens. 1976; 5:85-93

[42]Bremme K, Ostlund E, Almqvist I, et al. Enhanced thrombin generation and fibrinolytic activity in the normal pregnancy and the puerperium.// Obstet Gynecol. 2001;13: 115-119.

[43]Bremme KA. Hemostatic changes in pregnancy// Ballieres Best Pract Res ClinHaematol. 2003;16: 153-168."

[44]Brenner B, for the LIVE-ENOX Investigators. Efficacy and safety of two doses of Enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss:the LIVE-ENOX Study [abstract]// Blood. 2002;100:2765:702a.

138

[45]Brenner B, Hoffman R, Blumenfeld Z et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin // Thromb Haemost. 2000 May;83(5):693-7.

[46]Brenner B, Hoffman R, Blumenfeld Z et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin // Thromb Haemost. 2000 May;83(5):693-7."

[47]Brenner B. Haemostatic changes in pregnancy. Thromb. Res. 2004; 114 (5-6): 409-414

[48]Brill-Edwards P, Ginsberg JS, Gent M et al; Recurrence of Clot in This Pregnancy Study Group. Safety of withholding heparin in pregnant women with a history of venous thromboembolism // N Engl J Med.2000 Nov 16;343(20):1439"

[49]Bujold E, Roberge S, Lacasse Y et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta analysis// Obstet Gynecol. 2010 Aug;116(2 Pt 1):402-14.

[50]CAPRIE Steering Committee. A randomized, blinded. Trial of clopidogrel versus aspirin in patients at risk of ischemic events.// Lancet, 1996; 348:1329-1339

[51]Carbillon L., Uzan S. Early treatment with low-dose aspirin is effective for the prevention of preeclampsia and related complications in high-risk patients selected by the analysis of their historic risk factors // Blood 2005 105:902903; doi:10.1182/blood-2004-08-3268

[52]Carlin AJ, Farquharson RG, Quenby SM et al. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control // Hum Reprod. 2004 May;19(5):1211-4.

[53]Cattaneo M. Hyperhomocysteinemia and venous thromboembolism // Semin Thromb Hemost. 2006 Oct;32(7):716-23.

139

[54]Cervera R, Piette JC, Font J et al.; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients // Arthritis Rheum. 2002 Apr;46(4):1019-27.55.Chang J, Elam-Evans

[55]Chan P, Brown M, Simpson JM, Davis G. Proteinuria and preeclampsia how mach matters? BJOG 2005; 112(3):280-5

[56]Circulating platelet-derived and placenta-derived microparticles expose Flt-1 in preeclampsia. Reprod.Sci. 2008; 15 (10): 1002-1010

[57]Cockell AP, Learmont JG, Redman CW et al. Human placental syncytiotrophoblastmicrovillous membranes impair maternal vascular endothelial function. Br. J. Obstet.Gynaecol. 1997; 104(2): 235-240

[58]Cojocaru I.M., Cojocaru M, Musuroi C, Botezat M. Study of anti-cardiolipin and anti-beta2- glycoprotein I antibodies in patients with ischemic stroke. Rom J Intern Med. 2003; 41(2): 189-204.

[59]Coller B.S. Platelet GPIIb/IIIa antagonist: the first anti-integrin receptor therapeutics.// Clin. Invest., 1997; 99:1467-1471

[60]Coomarasamy A, Honest H, Papaioannou S et al. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review // Obstet Gynecol. 2003 Jun;101(6):1319-32.

[61]Coppola A, Davi G, De Stefano V et al. Homocysteine, coagulation, platelet function, and thrombosis // Semin Thromb Hemost. 2000;26(3):243-54

[62]Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb.Haemost .2005; 3 (8): 1800-1814

[63]Coulam CB, Wallis D, Weinstein J, DasGupta DS, Jeyendran RS. Comparison

of thrombophilic gene mutations among patients experiencing recurrent

140